NKGen Biotech Announces Early Interim Data From Phase 1 Cohort And Dosing Of First Phase 2 Patient In Trial Of Troculeucel For Moderate Alzheimer's Disease; Says 'Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found to have improved CDR-SB cognitive scores, resulting in a clinical upgrade from moderate AD to mild AD after only three months on therapy.'
Portfolio Pulse from Benzinga Newsdesk
NKGen Biotech has announced promising early interim data from its Phase 1/2a clinical trial of Troculeucel for moderate Alzheimer's Disease. Two out of three patients in the Phase 1 cohort showed improved cognitive scores after receiving the highest dose, indicating a potential shift from moderate to mild Alzheimer's Disease.
September 12, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NKGen Biotech's early interim data from its Alzheimer's trial shows promising results, with two patients improving from moderate to mild AD after high-dose treatment. This could positively impact the company's stock price.
The announcement of improved cognitive scores in patients treated with Troculeucel is a significant development for NKGen Biotech. Positive clinical trial results can lead to increased investor confidence and potentially drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100